Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biophytis ( (BPTSY) ) has issued an announcement.
On October 13, 2025, Biophytis announced a partnership with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first-ever Phase 3 trial in sarcopenia. This collaboration involves creating a joint venture in Hong Kong, with a $20 million investment from Asian investors, to develop and commercialize BIO101 in China, Japan, and Korea. The trial, expected to start in early 2026, aims to include up to 932 patients across Europe and Asia, potentially offering a significant advancement in treating sarcopenia, a disease affecting millions globally.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101, is a small molecule in development for muscular diseases such as sarcopenia and metabolic disorders like obesity. The company is headquartered in Paris, France, with subsidiaries in the USA and Brazil. Biophytis’ shares are listed on Euronext Growth Paris and its ADS on the OTC market.
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.96M
See more data about BPTSY stock on TipRanks’ Stock Analysis page.